文献速递乳腺癌

转移性乳腺癌中研究者与盲态独立中心评估的无进展生存期比较:系统综述与荟萃分析

Progression-Free Survival in Metastatic Breast Cancer by Local Investigators vs Blinded Independent Central Review: A Systematic Review and Meta-Analysis.
PubMed 文献 · JAMA Oncol · 2026-01-01

该系统综述与荟萃分析纳入21项随机对照试验、共9165例激素受体阳性/ERBB2阴性转移性乳腺癌患者,比较研究者评估与盲态独立中心评估(BICR)的无进展生存期(PFS)。总体差异指数为1.02(95%CI 0.95-1.10;P=.57),无统计学显著差异;试验组汇总PFS差异为0.26个月(95%CI -0.16至0.68个月;P=.22),对照组为0.44个月(95%CI 0.09-0.78个月;P=.01)。

要点

  • 总体研究者与BICR评估PFS无显著差异,差异指数1.02(95%CI 0.95-1.10)。
  • 试验组汇总PFS差异0.26个月(95%CI -0.16至0.68),无统计学意义。
  • 对照组BICR评估PFS较研究者评估略长0.44个月(95%CI 0.09-0.78;P=.01)。

核心结论

  • 在激素受体阳性/ERBB2阴性转移性乳腺癌随机对照试验中,BICR与研究者评估的PFS总体无统计学显著差异,差异指数为1.02(95%CI 0.95-1.10;P=.57)。
  • 尽管近期试验中BICR评估的中位PFS有延长趋势,但荟萃回归分析及离群试验中结果一致,提示两种评估方式所得PFS估计可比。

研究设计与样本

  • 纳入21项2期或3期随机对照试验,共9165例激素受体阳性/ERBB2阴性转移性乳腺癌患者,均报告研究者和BICR评估的PFS。
  • 由2名评价者提取数据,采用试验水平的随机效应荟萃分析。

主要发现

  • 总体研究者与BICR评估PFS的差异指数为1.02(95%CI 0.95-1.10;P=.57),无统计学显著差异。
  • 试验组汇总中位PFS差异为0.26个月(95%CI -0.16至0.68个月;P=.22)。
  • 对照组汇总中位PFS差异为0.44个月(95%CI 0.09-0.78个月;P=.01)。
  • 差异指数结果在荟萃回归分析中保持一致,在离群试验中亦一致。

关键数值与推荐

  • 差异指数(DI)定义为BICR与研究者评估PFS的风险比之比,总体DI为1.02(95%CI 0.95-1.10;P=.57)。
  • 绝对差异采用两种评估方式中位PFS之差,试验组为0.26个月(95%CI -0.16至0.68个月;P=.22),对照组为0.44个月(95%CI 0.09-0.78个月;P=.01)。

临床怎么用

  • 结果支持在激素受体阳性/ERBB2阴性转移性乳腺癌试验中,研究者评估与BICR评估的PFS可作为可比指标解读。
  • 对照组中BICR评估PFS略长的差异提示解读单臂或对照数据时需注意评估方式。
  • 对于以PFS为主要终点的试验设计,可参考本结果权衡是否常规采用BICR。

局限性

  • 纳入试验多为开放标签设计,可能影响评估偏倚的完全消除。
  • 仅7项试验要求既往CDK4/6抑制剂治疗后进展,人群代表性有限。
  • 分析为试验水平荟萃分析,未纳入患者个体数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Progression-free survival (PFS) is a widely accepted primary end point in metastatic breast cancer (mBC) trials; however, it remains susceptible to assessment bias. To reduce this risk, blinded independent central review (BICR) is often incorporated into trial designs, but emerging evidence has suggested discordance between investigator- and BICR-assessed PFS. OBJECTIVE: To compare BICR- and investigator-assessed PFS of patients with hormone receptor-positive/ERBB2-negative mBC. DATA SOURCES: PubMed, Embase, CENTRAL, and major conference proceedings were searched from database inception to November 27, 2025, to identify all potential eligible studies. STUDY SELECTION: Phase 2 or 3 randomized clinical trials (RCTs) including patients with hormone receptor-positive/ERBB2-negative mBC with progression following CDK4/6 inhibitor therapy. Eligible studies required or permitted prior CDK4/6 inhibitor use and reported PFS assessed by both local investigators and BICR. DATA EXTRACTION AND SYNTHESIS: Data from the eligible RCTs were extracted by 2 reviewers (L.V.R. and Z.B.). A trial-level random-effect meta-analysis was performed. MAIN OUTCOMES AND MEASURES: Outcomes were the discrepancy index (DI)-the ratio of hazard ratios for BICR- vs investigator-assessed PFS-and the absolute difference in median PFS between the 2 assessments. RESULTS: Of 4989 identified records, 21 RCTs with 9165 patients met inclusion criteria. Eleven RCTs used BICR as the primary assessment, 13 were open label, and 7 required prior treatment with CDK4/6 inhibitors as an inclusion criterion. No statistically significant difference was observed between investigator- and BICR-assessed PFS overall, with a DI of 1.02 (95% CI, 0.95-1.10; P = .57), which was consistent across meta-regression analyses. The pooled PFS difference was 0.26 months (95% CI, -0.16 to 0.68 months; P = .22) in interventional arms and 0.44 months (95% CI, 0.09-0.78 months; P = .01) in control arms. CONCLUSIONS AND RELEVANCE: Results of this systematic review and meta-analysis show that despite a trend toward longer median PFS with BICR in recent RCTs of patients with hormone receptor-positive/ERBB2-negative mBC, there was no statistically significant DI between BICR- and investigator-assessed PFS. Results were consistent across meta-regression analyses and in outlier trials, suggesting that both approaches yield comparable PFS estimates.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Ravani LV, Bagheri Z, Kalinsky K, et al. Progression-Free Survival in Metastatic Breast Cancer by Local Investigators vs Blinded Independent Central Review: A Systematic Review and Meta-Analysis. JAMA Oncol. 2026. PMID: 42461660. doi:10.1001/jamaoncol.2026.1571

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。